2025 Biopharma M&A Booms: Patent Cliff Spurs Big Pharma to Secure Late-Stage Assets
Biopharma M&A in 2025 shifted to fewer but mu...
Headline acquisitions such as J&J–Intra-Cellu...
Patent cliffs threaten roughly $180–230 billi...
Deal structures feature heavier use of milest...
Headline acquisitions such as J&J–Intra-Cellu...
Patent cliffs threaten roughly $180–230 billi...
Deal structures feature heavier use of milest...










